Skip to main content

Warwick Medical School joins forces with Novo Nordisk to improve diabetes care

(Thursday 29th Sept, 2005) - today the University of Warwick announced the signing of a partnership agreement between Warwick Medical School and Danish diabetes healthcare company Novo Nordisk, focusing on a joint initiative to improve clinical research in diabetes medicine. The partnership will support the advance of treatment guidelines for primary and secondary care and further drive education elements for health care practitioners.

Approximately 1.4 million people are known to suffer from diabetes in the UK and a recent audit by the Healthcare Commission, August 2005, suggests that about 1 in 4 people with the disease are currently undiagnosed. The audit also indicates that diabetes is not being managed adequately and many people are at high risk of complications including blindness and kidney disease if the rates of prevention, detection and management are not significantly improved.

The University of Warwick is one the UK's top ten research Universities and Warwick Medical School has developed particular research strengths in diabetes research.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.

Professor Yvonne Carter Dean of Warwick Medical School at the University of Warwick said: "Around one in ten of all hospital admissions in the NHS are diabetes related. This agreement between one of the UK's leading research universities, the largest national healthcare system in the world, and the leaders in diabetes care from private industry, unites us in the fight against the world's fastest growing chronic disease."

Viggo Birch, Managing Director, Novo Nordisk, said: "Our vision is to defeat diabetes, but we cannot do it alone. Novo Nordisk is always looking to develop partnerships to improve treatments, patient education and support healthcare professionals. So we must break down the false barriers between industry, government and academia and learn to work together. We are very much looking forward to working with the University of Warwick and continuing to support the NHS to achieve these united goals."

Worldwide there are 150 million people living with diabetes and the pandemic is estimated to affect 220 million people by 2015, making it one of the most challenging medical problems of the 21st century.

ENDS

For further information please contact:

Peter Dunn
Press and Media Relations Manager
University of Warwick
Tel: 024 7652 3708
Mob: 07767 655860
Email: p.j.dunn@warwick.ac.uk


Conor Griffin
Communications Manager
Novo Nordisk
Tel: 01293 613 555
Mob: 0778 6874285
cgff@novonordisk.com

NOTES TO EDITORS:
About Novo Nordisk:
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.

In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.

With headquarters in Denmark, Novo Nordisk more than 20,000 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.